» Articles » PMID: 30183655

Autoimmune Aspects of Kawasaki Disease

Overview
Date 2018 Sep 6
PMID 30183655
Citations 53
Authors
Affiliations
Soon will be listed here.
Abstract

Kawasaki disease (KD) is a vasculitis that is part of systemic vasculitis syndrome. It affects medium-sized vessels and is characterized by hypercytokinemia. Although the etiology of KD remains unidentified, epidemiological features point to the role of infection and genetic predisposition. Recent studies on KD revealed endothelial damage and resultant thrombin generation, as well as B-cell activation during the acute phase. Several antiendothelial cell autoantibodies (AECAs) have been identified in KD patients. Analysis of this phenomenon together with the recently developed concept of immunothrombosis reveals a potential pathogenic mechanism for KD. First, polyclonal antibodies generated against invading microorganisms would exhibit cross-reactivity toward endothelial cell components and become dominant during affinity maturation. Binding of AECAs to endothelial cells would cause endothelial activation or damage, with proinflammatory cytokine release, thus fostering a hypercoagulable state resulting from leukocyte activation by proinflammatory cytokines. This, in turn, would lead to coronary artery lesions. KD vasculitis might be initiated upon binding of AECAs to the vasa vasorum and progress to panvasculitis and a vulnerable vessel wall, resulting in an aneurysm. The aneurysm would cause flow recirculation and alteration of wall shear stress. Consequently, platelets activated by shear stress, along with ultralarge von Willebrand factor (VWF) released by endothelial cells, would cause platelet-driven arterial thrombosis. Autoimmunity-associated thrombosis initiated by binding of AECAs to endothelial cells might play a major role in the pathogenesis of certain subtypes of KD. The notion of KD consisting of subtypes, the major one of which is AECA-associated vasculitis, will help improve our understanding of KD and further promote early and accurate diagnosis, which remains challenging.

Citing Articles

Identification of key ferroptosis‑related biomarkers in Kawasaki disease by clinical and experimental validation.

Yan R, Chen S, Lang X, Liu J, Zhou T Biomed Rep. 2024; 22(1):16.

PMID: 39624783 PMC: 11609609. DOI: 10.3892/br.2024.1894.


Targeting PDGF/PDGFR Signaling Pathway by microRNA, lncRNA, and circRNA for Therapy of Vascular Diseases: A Narrow Review.

Ma C, Shi S, Zhang X, Xin G, Zou X, Li W Biomolecules. 2024; 14(11).

PMID: 39595622 PMC: 11592287. DOI: 10.3390/biom14111446.


The Future of Kawasaki Disease Diagnosis: Liquid Biopsy May Hold the Key.

Markandran K, Clemente K, Tan E, Attal K, Chee Q, Cheung C Int J Mol Sci. 2024; 25(15).

PMID: 39125631 PMC: 11311979. DOI: 10.3390/ijms25158062.


Whole patient knowledge modeling of COVID-19 symptomatology reveals common molecular mechanisms.

Brock S, Jackson D, Soldatos T, Hornischer K, Schafer A, Diella F Front Mol Med. 2024; 2:1035290.

PMID: 39086962 PMC: 11285600. DOI: 10.3389/fmmed.2022.1035290.


Identification of a mimotope of a complex gp41 Human Immunodeficiency VIrus epitope related to a non-structural protein of previously implicated in Kawasaki disease.

Sojar H, Baron S, Hicar M bioRxiv. 2024; .

PMID: 38979252 PMC: 11230383. DOI: 10.1101/2024.06.26.600771.